Songdo Biopharmaceutical Cluster

Songdo International City in Incheon hosts the largest concentration of biopharmaceutical manufacturing capacity in Asia, anchored by Samsung Biologics (5 plants) and Celltrion (3 plants). The district's proximity to Incheon International Airport, its free economic zone status, and purpose-built infrastructure have attracted additional global biotech companies including AGC Biologics and domestic startups.

The cluster model creates self-reinforcing advantages: shared talent pools, specialized suppliers (media, chromatography resins, single-use components), regulatory expertise, and logistics infrastructure. Samsung Biologics and Celltrion together employ over 10,000 biopharmaceutical specialists, creating a labor market depth that no single company could sustain alone.

The Korean government's K-Bio CDMO Support Act provides regulatory fast-tracking, tax incentives, and infrastructure investment specifically for the Songdo cluster and similar bio hubs in Osong and Daejeon. The goal is to make Korea the "Samsung of pharma manufacturing" — not inventing the drugs, but manufacturing them at the highest quality and lowest cost globally.